The prevalence of a genetic polymorphism(s) at codon 268 in the cytochrome b gene, which is associated with failure of atovaquone-proguanil treatment, was analyzed in 227 Plasmodium falciparum parasites from western Kenya. The prevalence of the wild-type allele was 63%, and that of the Y268S (denoting a Y-to-S change at position 268) mutant allele was 2%. There were no pure Y268C or Y268N mutant alleles, only mixtures of a mutant allele(s) with the wild type. There was a correlation between parasite 50% inhibitory concentration (IC 50 ) and parasite genetic polymorphism; mutant alleles had higher IC 50 s than the wild type.
A tovaquone-proguanil (AP) is a fixed-dose combination antimalarial drug, mostly used for treatment and chemoprophylaxis of falciparum malaria for international travelers (1) . Use of atovaquone alone leads to high rates of treatment recrudescence (2) , which is attributed to mutations in the cytochrome b gene (pfcytb) (3) . Plasmodium falciparum atovaquone-resistant isolates have been described following atovaquone or AP treatment failures (4) (5) (6) (7) (8) (9) (10) (11) and in vitro drug susceptibility testing (5, 8, 10, 12) . In vitro and in vivo resistance to atovaquone has been associated with point mutations at codon 268 in pfcytb (5, 9, 10, 13) . These mutations include Y268S (denoting the Y-to-S change at position 268), Y268N, and Y268C (5, 9, 11, 13, 14) and can induce a Ͼ1,000-fold increase in atovaquone 50% inhibitory concentration (IC 50 ) (13, 15) . There are cases of AP treatment failure for travelers returning from Africa (4-6, 9-11, [16] [17] [18] [19] and appearance of pfcytb mutations following AP treatment (4-6, 9-11, 14) . However, treatment failure is not always associated with a known pfcytb mutation (17, 18, 20, 21) , indicating that other factors such as genetic polymorphisms in other genetic loci play a role in AP resistance.
Kenya has a large number of international travelers and foreign residents who use AP for malaria prophylaxis. Additionally, AP is one of the second-line treatment options for uncomplicated malaria (22) . In this study, a baseline epidemiological surveillance study was conducted to determine the prevalence of a genetic polymorphism(s) at codon 268 of pfcytb in Kenyan P. falciparum parasites. Field clinical isolates from an ongoing approved malaria epidemiological surveillance protocol (KEMRI SSC document 1330 and WRAIR document 1384), collected between 2008 and 2012 from three locations in Kenya (Kisumu, Kisii, and Kericho), were randomly selected for inclusion in the study. Kisumu is a lowland where malaria is endemic, with highly stable transmission, whereas Kisii and Kericho are highlands, with unstable transmission (23) . Sample collection and preparation were performed as previously described (24) . Genomic DNA from whole blood was extracted using a Qiagen DNA minikit (Qiagen, Valencia, CA) as recommended by the manufacturer. Clinical isolates were culture adapted before being subjected to the SYBR green I assay as previously described (25) . A total of 227 (167 from Kisumu, 37 from Kisii, and 23 from Kericho) samples were successfully analyzed by PCR-restriction fragment length polymorphism (RFLP) at codon 268 as previously described (10), and a subset (n ϭ 68) of the samples was sequenced to confirm PCR-RFLP results using an ABI Prism 3500xL genetic analyzer (Applied Biosystems, Foster City, CA) as previously described (10) . Reference strain sequences were used to score the genotype.
Data revealed that none of the samples carried a pure Y268C or Y268N mutant allele. Sixty-three percent of the isolates carried the wild-type (WT) allele, and 2% carried the Y268S mutant allele. Thirty-three percent had a double mixed genotype (WT/Y268S), and 3% had a triple mixed genotype (WT/Y268S/Y268N). Interestingly, 100% ( Table 1 ). Figure 1 shows the atovaquone IC 50 s for parasites collected from 2008 to 2012. The median IC 50 (interquartile range [IQR] ) for the control reference strain, 3D7, was 1.68 nM (1.09 to 2.70 nM). The median (IQR) IC 50 for all isolates in this study was 3.5 nM (1.4 to 8.4 nM). The IC 50 cutoff points used for sensitive and resistant parasites were set at Ͻ30 nM and Ͼ1,900 nM, respectively (8) . Based on these criteria, only 1.3% isolates had high IC 50 s, between 1,121 nM and 2,250 nM. Comparison of the median IC 50 s from year to year revealed that there was a significant difference (P ϭ 0.0003; Kruskal-Wallis H statistics) ( The median (IQR) IC 50 for parasites carrying the WT allele was 3.0 nM (1.0 to 6.9 nM), whereas the median (IQR) IC 50 for the parasites carrying the pure Y268S mutant was 5.7 nM (1.7 to 1,216 nM). The median (IQR) IC 50 for parasites carrying the WT/Y268S mixture was 4.7 nM (2.2 to 11.1 nM), whereas the median (IQR) IC 50 for parasites carrying the WT/Y268S/Y268N mixed genotype was 5.0 nM (2.0 to 11.8 nM). The differences in median IC 50 for the different parasite genotypes reached statistical significance (P ϭ 0.0106; Kruskal-Wallis H statistics).
The current study describes the presence of the Y268S mutant allele in samples collected in Kenya. None of samples carried the pure Y268C or Y268N mutant allele. Interestingly, however, there was a large number of samples carrying the WT/Y268S mixed genotype. The Y268N mutant allele occurred only in mixed genotypes, with these samples carrying the WT/Y268S/Y268N mixed genotype. To the best of our knowledge, this is the first study to describe the presence of mixed genotypes at codon 268 in the pfcytb gene carrying the WT allele and one or two mutant alleles.
Mutations in the pfcytb gene have been shown to arise de novo due to AP selection (9, 11) . However, although low in prevalence, these mutations have been shown to occur in parasite populations even in locations where there is no AP pressure (26) . AP is minimally used for control of malaria and for treatment of Pneumocystis jirovecii pneumonia in patients with HIV infection who cannot tolerate trimethoprim-sulfamethoxazole (27) (28) (29) . In the current study, 2% of the sample parasites had the Y268S mutant allele.
Interestingly, a large number of samples (35%) were the WT/ Y268S or WT/Y268S/Y268N mixed genotype, carrying a mutant allele(s); 95% of these samples were from Kisumu and 5% from Kisii, but none were from Kericho. Studies have demonstrated that parasite genomic polymorphisms result in fitness consequences and that parasites will not maintain any polymorphism that is not beneficial (30) (31) (32) . Further studies will be required to determine whether these mutations would appear in nature at such high proportions without any selection pressure. Given the overwhelming occurrence of these mutations is in Kisumu, a high-transmission region, it will be interesting to investigate if there is any correlation. It will also be critical to determine if these mutations confer any other benefit(s) to parasite survival to warrant such high prevalence. Interestingly, there seems to be a correlation between HIV prevalence and prevalence of mutations at codon 268; Kisumu has the highest HIV prevalence (19.3% of the population), compared to Kisii (8%) and Kericho (3.4%) (33) . It is likely that the use of AP or other drugs to control opportunistic infections in HIV-infected populations exerts pressure on the parasite population.
The current study also describes the temporal trends of mutations at codon 268 in pfcytb and the IC 50 s for the samples collected in Kenya between 2008 and 2012. There were fluctuations of genotype and median IC 50 throughout the study period. Of interest is the emergence of the Y268S mutant allele in the final 3 years of the study. Also, the frequency of mixed genotypes carrying a mutant allele(s) remained high throughout, indicating that the selection pressure remained sustained throughout the study period.
In a study that analyzed the atovaquone in vitro susceptibility of isolates from Africa, one sample carrying Y268S, isolated from a patient for which AP treatment failed, had an IC 50 of 8,230 nM (8). In another study, the IC 50 for a parasite with Y268N, isolated from a patient who recrudesced after AP treatment, was 1,888 nM (5). The median IC 50 for parasites in the current study was 3.5 nM, well within the range previously shown (8, 32 In conclusion, we have shown that AP resistance-associated mutations are present in Kenyan parasites. The pure mutant (Y268S) exists at a low prevalence, but interestingly, the prevalences of double and triple mixed genotypes are relatively high. These mutations are overwhelmingly prevalent in Kisumu, a hightransmission region. These data are puzzling, given that AP has not been widely used in Kenya for treatment of malaria. More studies are required to further elucidate our findings.
Nucleotide sequence accession numbers. All sequences were deposited in GenBank under accession numbers KP293776 to KP293843.
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